Company ProfilePremium

Biocartis Group NV

Company Profile Analysis

Ticker: BCART.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Biocartis Group NV - Company showcase

Year Founded & Workforce

2007

526 Employees

Biocartis Group NV logo

Biocartis Group NV Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Biocartis Group NV Overview

FieldBiocartis Group NV (listed entity, in liquidation)Continuing operating business
Legal nameBiocartis Group NV (in vereffening / in liquidation)Biocartis NV (Belgium); Biocartis US Inc. (USA); parent Biocartis Holdings Inc.
Former names / predecessorsBiocartis SA (Lausanne, Switzerland) was the original group vehicle; the group later redomiciled to Mechelen, Belgium (date not re-verified)Same Idylla business; "New Biocartis" in 2023 restructuring documents
Founding year2007 (company and aggregator profiles)2007 (business origin)
Incorporation jurisdictionBelgium (NV under the Belgian Code of Companies and Associations)Biocartis NV: Belgium; Biocartis US Inc.: USA; Biocartis Holdings Inc.: not publicly disclosed (US corporation per name; state not disclosed)
HeadquartersGeneraal de Wittelaan 11B, 2800 Mechelen, BelgiumMechelen, Belgium (manufacturing and R&D); US operations (location not publicly disclosed in sources reviewed)
Exchange / tickerEuronext Brussels: BCART (trading suspended by FSMA in September 2023; some data vendors classify it as delisted since September 2023); US OTC quote BIOGF (inactive)Not listed
ISINBE0974281132—
LEI549300J4HOJL5KG8HY54 (financialfilings.com)—
CUSIPNot applicable / not publicly disclosed—
Fiscal year end31 December31 December (assumed; not publicly disclosed)
Employees526 full-time (Yahoo Finance profile, latest reported group figure, likely FY2022). After the 2023 transfer the listed entity has effectively no operating staff.About 200 employees in Mechelen (Made in / KBC Securities commentary, August 2025)
Auditornot re-verified)—
Market capitalisationEffectively nil economic value. Last trade about EUR 0.29/share in September 2023; about EUR 27.2M on about 93.9M shares (Parqet/Craft aggregator data)Private; valuation not publicly disclosed
Websitebiocartisgroupnv.be (investor/liquidation notices); historical biocartis.combiocartis.com
LiquidatorMr. Kristiaan Caluwaerts (appointed 15 December 2025)—
Controlling ownersShareholders of the shell have no residual claim on the operating businessFormer secured bondholders and first-lien lenders. KBC Securities identifies US hedge funds Whitebox and Highbridge as the key holders (Made in, 28 August 2025)
MetricFY2020FY2021FY2022
Group FTE headcount (number)——526

The 526 figure comes from the Yahoo Finance profile and its reference year is not stated. A cost-reduction and operational reorganisation programme announced on 15 June 2023 cut functions during 2023 (H1 2023 results release, 26 September 2023). Around 200 Mechelen jobs were reported as maintained under the new owners in August 2025.

Biocartis built Idylla, a fully automated, cartridge-based real-time PCR system that runs "sample-to-result" molecular tests directly from routine clinical samples, notably formalin-fixed paraffin-embedded (FFPE) tumour tissue, in about three hours with minimal hands-on time. Its strategic niche was decentralised oncology biomarker testing (BRAF, KRAS, NRAS, EGFR, MSI, gene fusions) for hospital pathology labs that lack next-generation sequencing (NGS) capacity or need faster turnaround than send-out sequencing. Commercial traction was real: about 2,200 instruments installed and more than 330,000 cartridges a year by 2022–2023. Losses were structural, however: cumulative losses approached EUR 0.5 billion, and a EUR 150M convertible bond overhang proved unserviceable. The listed holding company was hollowed out by creditor enforcement in October 2023 and is now in judicial liquidation. The operating franchise survives privately and has since won its first FDA premarket approval for a companion diagnostic (Idylla CDx MSI, September 2025).


What the company does

Biocartis develops, manufactures and sells the Idylla molecular diagnostics platform. The system has three parts:

  • the Idylla Instrument, a cartridge-processing module, with several modules connectable to one console;

  • the Idylla Console, the user interface and data management unit;

  • single-use Idylla cartridges, each a self-contained assay with all reagents pre-loaded.

The user places a sample, such as an FFPE tissue slice, plasma or a swab, into the cartridge. The cartridge performs liquefaction and nucleic-acid extraction, amplification and real-time PCR detection with no further intervention. The company describes Idylla's proprietary liquefaction sample preparation as the reason it can handle difficult samples such as small tissue biopsies and FFPE material (CEO Roger Moody, 360Dx interview, September 2025).

The menu historically covered two areas:

Oncology: (core): mutation tests for colorectal cancer, lung cancer and melanoma; MSI status; a lung gene-fusion panel; plus research-use assays and partner-developed tests such as Merlin (SkylineDx, melanoma), Hepatopredict (Ophiomics, liver cancer) and ColonoDETECT.

Infectious disease: Idylla SARS-CoV-2 and SARS-CoV-2/Flu/RSV panels, and the SeptiCyte RAPID host-response sepsis test (licensed from Immunexpress).

Business model and revenue model

Revenue streamDescriptionFY2022 figure (EUR Mn)Share of FY2022 revenue
Cartridge sales (product)Consumable assays: oncology plus infectious disease35.9about 62%
Instrument sales and rentals (product)Idylla systems sold to end users and content partners, plus rental income9.2about 16%
Collaboration revenueR&D services and milestones from pharma CDx partners and content partnersabout 12 (derived)about 21%
Service revenueInstrument servicingincluded above (service revenue was EUR 1.7M in FY2021)about 2–3%
Total revenue—57.5100%

Biocartis ran a classic razor/razor-blade installed-base model. Instruments were sold, rented or placed free under evaluation programmes, and recurring revenue came from cartridge consumption. Revenue had four lines:

Source: Biocartis FY2022 results press release, 23 February 2023. Collaboration plus service is derived as total revenue (57.5) minus product revenue (45.0). There was no subscription model. Licensing appeared mainly in-bound, with partner content (Immunexpress, SkylineDx, Ophiomics, GeneproDx) commercialised on Idylla, sometimes under revenue-share arrangements.

Pricing signals disclosed:

  • Average selling price (ASP) per commercial cartridge: EUR 106 in FY2022 versus EUR 96 in FY2021; oncology ASP EUR 116 (+11%) (FY2022 results).

  • Oncology ASP in Q1 2022: EUR 114; all products: EUR 101 (GenomeWeb, Q1 2022).

  • Free evaluation programme: a customer could temporarily use an instrument while paying only for cartridges consumed (FY2022 results).

Value-chain position

Biocartis was vertically integrated from assay design to manufacturing. Cartridges were produced in Mechelen, including a high-throughput, fully automated manufacturing line that was ramping in 2022, and the company sold through a hybrid of direct sales (Europe, US) and distributors:

  • Nichirei Biosciences in Japan;

  • third-party distributors in rest-of-world markets.

Pharma companies acted both as customers, funding companion diagnostic (CDx) development, and as demand creators, because a CDx label pulls testing into labs.

Customers and end-markets

Customer typeRoleEvidence
Hospital pathology and molecular labsCore users of oncology cartridgesSeveral new top-10 cancer centres adopted Idylla in 2022 (FY2022 results)
Reference and community labs (US)Growth target of the US go-to-market model from 2019New US direct sales strategy, September 2019
Pharmaceutical companiesCDx development partners funding R&DAmgen (RAS), Bristol Myers Squibb (MSI), AstraZeneca (EGFR/osimertinib CDx)
Content partners / diagnostic developersPort their tests onto IdyllaSkylineDx, Ophiomics, Immunexpress, GeneproDx, Apis Assay Technologies, HiloProbe
Clinical trial sponsorsInstruments for trial sitesClinical-trial-driven instrument purchases deferred into 2023 (Q3 2022 update)
Academic medical centresResearch collaborations on new signaturesMayo Clinic, Medical College of Wisconsin, City of Hope (2026)

Company self-description versus independent characterisation

Company's own description (paraphrased from "About Biocartis" boilerplate, 2022–2023 releases): Biocartis presents itself as an innovative molecular diagnostics company whose proprietary, fully automated Idylla platform aims to make precision medicine accessible by delivering fast, accurate molecular information from virtually any biological sample, with a continuously expanding oncology menu.

Independent characterisation: Biocartis was a technologically differentiated but sub-scale single-platform MDx vendor. It was caught between two groups:

  • integrated rapid-PCR players with large installed bases and broad infectious-disease menus, notably Cepheid's GeneXpert;

  • an oncology testing paradigm that steadily shifted toward multi-gene NGS panels.

Idylla's sweet spot was single-gene or small-panel testing where speed and tissue economy matter. That segment is real but narrower than the company's early-stage valuation implied. Revenue grew at about 15% CAGR from FY2019 to FY2022, but gross margin on products only reached the mid-30s percent in 2022 and 40% in H1 2023. Operating cash burn stayed far above revenue capacity, which ultimately transferred the equity to creditors.

Strategy

Stated strategy themes (last listed period, 2022–2023)

  1. Drive profitable growth: grow product revenue, expand product gross margins through ASP increases and manufacturing automation, and cut operating cash burn (2022 key objectives, 17 January 2023 release).

  2. Oncology focus: concentrate on high-value oncology cartridges and de-emphasise infectious disease after COVID-19.

  3. Menu expansion via partners: become an open platform for third-party content (SkylineDx, Ophiomics, Apis, HiloProbe, GeneproDx, Immunexpress).

  4. Pharma CDx: secure CDx claims (BMS MSI, AstraZeneca EGFR, Amgen RAS) to pull Idylla into standard-of-care testing.

  5. US commercial build-out: direct sales model; the CEO appointment in 2023 was explicitly aimed at US commercial success.

Initiatives in the last 24 months (operating business, October 2024 – October 2026)

DateInitiativeTypeStrategic intent
Mar 2025Multiple USCAP 2025 abstracts on IdyllaClinical evidenceBuild real-world utility data
2 Jun 2025IVDR Class C CDx certification, Idylla EGFR Mutation TestRegulatorySecure EU market access under IVDR
Jun–Aug 2025New SVPs in Global Marketing (Svarczkopf) and Global Business Development (Kreitzinger)LeadershipCommercial and partnering push
15 Sep 2025FDA PMA for Idylla CDx MSI Test (with BMS)Regulatory / CDxFirst US CDx; reposition as the "sample-to-result CDx" platform
Nov 2025AMP 2025 showcaseMarketingUS lab adoption
12 Jan 2026Mayo Clinic collaboration (breast cancer gene signatures)R&D partnershipMove up the value chain into multigene signatures
10 Mar 2026IVDR CDx certification for Idylla CDx MSIRegulatoryEU CDx parity
24 Mar 2026Medical College of Wisconsin collaboration (breast signatures)R&D partnershipSame
9 Jun 2026City of Hope agreement (pancreatic cancer early-detection signature)R&D partnershipEntry into early detection
7 Jul 2026Discovery Life Sciences strategic collaborationCommercial / biopharma servicesAccess biopharma trial and biospecimen ecosystem

Cost programmes and targets

2022: target to cut operating cash burn by EUR 9.5M–13.5M; actual reduction was EUR 18.1M.

2023: EBITDA guidance of EUR -25M to -28M. A reorganisation and cost-reduction programme announced 15 June 2023 had targets that were not fully disclosed in the sources reviewed.

Post-restructuring plan: the EUR 40M new equity was meant to fund the business to EBITDA break-even by end-2024 (recapitalisation release, 26 September 2023). By September 2025 the CEO said the company was on a pathway to profitability "within the next year", which implies break-even slipped by at least a year.

ESG commitments

No quantified ESG targets were disclosed. Sustainability reports were published from 2015 to 2022 (sustainabilityreports.com index lists nine reports).

Medium-term targets

No current financial guidance exists for the listed entity, which is in liquidation. The operating business has disclosed no quantified medium-term targets beyond the profitability ambition above.

Products & Services

All products sit within the single Idylla segment.

Platform hardware

ProductDescription and capabilitiesTarget customerLaunch / latestNotes
Idylla InstrumentCartridge-processing module running automated sample prep, PCR and detection; modules stackable on one consolePathology and molecular labsc. 2014 launch (not re-verified); China approval 2022Installed base 2,218 at end of H1 2023
Idylla ConsoleTouch-screen control and data unit linking multiple instrumentsSamec. 2014Part of the system
Idylla FLEXPlatform enhancement announced February 2023 to increase flexibility (detailed specifications not publicly disclosed in sources reviewed)Labs, content partners2,023Q1 2023 release links

Oncology tests: IVD / CDx

TestClinical useKey featuresRegulatory status (latest known)
Idylla BRAF Mutation TestMelanoma / colorectal BRAF V600 statusFFPE-to-result, about 90 minutes to 3 hoursCE-IVD (Europe)
Idylla KRAS Mutation TestColorectal cancer therapy selectionFFPECE-IVD; Amgen RAS collaboration
Idylla NRAS-BRAF Mutation TestColorectal cancer / melanomaFFPECE-IVD
Idylla EGFR Mutation TestNSCLC EGFR statusFFPEIVDR Class C CDx certification (2 June 2025); AstraZeneca CDx collaboration for osimertinib
Idylla MSI TestMicrosatellite instability in colorectal cancer (Lynch screening / immunotherapy selection)Seven novel MSI biomarkers; no matched normal tissue required (not re-verified)CE-IVD 2019; Japan approval via Nichirei 2022
Idylla CDx MSI TestCompanion diagnostic for colorectal cancer, developed with Bristol Myers SquibbFirst fully automated cartridge-based CDx approved in the US for CRCFDA PMA (15 September 2025); IVDR Class C CDx (10 March 2026)
Idylla GeneFusion PanelNSCLC fusion screening (ALK, ROS1, RET, NTRK, MET exon 14; not re-verified)Lower tissue requirement, faster turnaround than standard methodsCE-IVD, launched 20 June 2022
Idylla ctEGFR Mutation AssayEGFR from plasma (liquid biopsy)Research useLaunched 2019

Oncology: partner-content and research assays

AssayPartnerUseStatus
Merlin Assay (CP-GEP)SkylineDxMelanoma: identifies patients who may safely forgo sentinel lymph node biopsyEuropean commercialisation started September 2022
Idylla HepatopredictOphiomicsLiver cancer: transplant/resection eligibility prognosticPartnership February 2022
ColonoDETECT—ColorectalListed in portfolio (roic.ai)
ThyroidPrintGeneproDxThyroid nodule genomic classifierLicense, development and commercialisation agreement
Breast cancer subtyping assayApis Assay TechnologiesBreast cancer molecular subtypingAgreement April 2023
Colorectal cancer testHiloProbeCRCCollaboration 2023
Oncology research assays (RUO)In-houseBiomarker researchOngoing

Infectious disease

TestUseStatus
Idylla SARS-CoV-2 TestCOVID-19 PCRLaunched 2020; revenue fell from EUR 6.8M (FY2021, derived) to EUR 3.5M (FY2022) and EUR 0.7M (H1 2023)
Idylla SARS-CoV-2/Flu/RSV PanelRespiratory multiplexLaunched (year not re-verified)
SeptiCyte RAPID on IdyllaHost-response test to distinguish sepsis from non-infectious systemic inflammation (Immunexpress)Market release announced (year not re-verified)

Pipeline (operating business, 2025–2026)

ProgrammeDescriptionSource
ESR1 testSupported by preliminary SERENA-6 trial data (breast cancer, ESR1 mutations)CEO Moody, 360Dx, September 2025
Breast cancer gene signaturesCollaborations with Mayo Clinic (January 2026) and Medical College of Wisconsin (March 2026)Biocartis newsroom
Pancreatic cancer early-detection signatureRapid gene-signature test with City of HopeBiocartis newsroom, 9 June 2026
PCR-based cancer panel reimbursement advocacyUS policy agenda360Dx, September 2025

Services

Instrument servicing and maintenance, a free evaluation and placement programme, and R&D services to pharma and content partners (collaboration revenue).

Financial Narrative

Basis: IFRS as adopted by the EU, EUR millions unless stated. The five fiscal years are FY2019–FY2023, the last five years of the listed group's reporting. FY2024 and FY2025 are not applicable: after 31 October 2023 the listed group had no operating business, and the private operating group does not publish accounts.

Primary limitation: FY2023 full-year audited figures were delayed (the annual report was postponed in May 2024). FY2023 columns are therefore mostly blank, and the H1 2023 data is the most reliable late-period information.

Income statement

Sources and notes:

  • FY2019–FY2021 revenue, net loss, EPS, R&D and SG&A: GenomeWeb/360Dx summaries of results releases. Total operating income FY2020–FY2022: Biocartis results releases.

  • FY2022: Biocartis FY2022 results (23 February 2023) and GenomeWeb.

  • FY2022 gross profit (27.7) and the alternative net loss (-65.4) and EBITDA (-44.3) come from Parqet aggregator data. Discrepancy: GenomeWeb reports an FY2022 net loss of EUR 47.7M (EPS -0.79), while Parqet shows -65.4M. The gap may reflect gains on convertible bond repurchases or different line definitions. The primary-source-adjacent GenomeWeb figure is used in the table.

EBITDA derivation: FY2023 guidance was EBITDA of EUR -25M to -28M, an improvement of EUR 8.5M–11.5M, which implies FY2022 EBITDA of about EUR -36.5M. That conflicts with Parqet's -44.3M. FY2021 EBITDA is not directly disclosed; -46.0 is an estimate from FY2021 operating cash burn of EUR 56.6M less assumed capex of about EUR 10M and should be treated as indicative only.

  • Diluted EPS equals basic EPS in all years given losses (anti-dilutive instruments).

  • FY2018 reference: revenue EUR 27.8M; net loss EUR 48.2M; EPS -0.94.

Margins and growth

Product gross margin is gross profit on product sales divided by product revenue. Management reported a 34% year-end 2022 gross margin, 35% in Q1 2023 and 40% in H1 2023. Net margin uses GenomeWeb net loss figures.

Revenue CAGR FY2019–FY2022: about 15.4% total revenue and about 23.2% product revenue (derived).

Balance sheet

Sources: annual results summaries; the FY2021 cash figure includes EUR 6.0M drawn on short-term facilities; the 2023 restructuring figure is from the recapitalisation release of 26 September 2023.

The following balance-sheet items were not publicly disclosed in the sources retrieved: total assets, equity, goodwill and intangibles, working capital, and the short/long-term split of total debt for FY2019–FY2022. The qualitative capital structure is set out below.

Capital structure evolution:

Shares outstanding: about 93.92M (Parqet).

Cash flow

Sources and notes:

  • Operating cash burn: Biocartis results releases (FY2022: "a reduction of more than a third").

  • Net change in cash is derived from year-end cash balances and includes financing flows.

  • Operating cash flow, capex and free cash flow as separate lines are not publicly disclosed in the sources retrieved. The operating cash burn measure (EBITDA plus capex) is the company's own free-cash-flow proxy.

Ratios

ROE, ROA, ROIC, current ratio, debt/equity, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful or not publicly disclosed. EBITDA and net income were negative throughout, and Parqet reports a negative price-to-book of -0.58, indicating negative book equity by 2023. The December 2025 court judgment confirmed negative net equity as the legal ground for dissolution.

Commentary: trends, inflections and drivers

FY2019–FY2020: growth phase financed by IPO and convertible cash.

  • Revenue rose from EUR 27.8M (FY2018) to EUR 43.1M (FY2020).

  • The installed base grew from 1,310 to 1,581 instruments, and cartridge volume from about 175k to about 230k (+31%).

  • Net losses held at about EUR 63–64M a year as R&D climbed to EUR 45.8M, above 100% of revenue.

  • Cash fell from EUR 178.7M to EUR 123.7M.

  • COVID-19 disrupted instrument placements in H1 2020 (101 versus 156 a year earlier) but brought a temporary infectious-disease tailwind via Idylla SARS-CoV-2.

FY2021: the inflection that never paid off.

  • Product revenue grew 27% to EUR 40.5M, but collaboration revenue fell 39% to EUR 6.1M.

  • A manufacturing-line fire interrupted the high-throughput line.

  • The net loss peaked at EUR 71.5M, and cash dropped to EUR 53.5M (including EUR 6M of drawn facilities).

  • The 2022 guidance of EUR 50–55M product revenue proved far too optimistic.

FY2022: margin repair, guidance miss and recapitalisation.

  • Product revenue reached EUR 45.0M, missing the original EUR 50–55M guidance; it was revised down to "at least EUR 45M" in October 2022 because of deferred clinical trials, customer destocking and greater use of free evaluations.

  • Product gross profit more than doubled, from EUR 6.6M to EUR 15.2M, thanks to rising oncology ASPs (EUR 116) and automation scale effects.

  • Operating cash burn fell by EUR 18.1M to EUR 38.5M.

  • Cash nonetheless fell to EUR 26.1M, and the company needed the EUR 66M rescue package, which pushed further debt onto the balance sheet.

FY2023: operational improvement overtaken by the capital structure.

  • H1 2023 revenue grew 12% to EUR 29.5M, gross margin reached 40% and EBITDA improved to EUR -14.5M.

  • Total debt of more than EUR 170M (EUR 132M of bonds plus secured loans) against a market cap below EUR 30M meant equity holders were out of the money.

  • Creditors chose enforcement over another dilutive refinancing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue stream (EUR Mn)

Revenue stream (EUR Mn)FY2019FY2020FY2021FY2022FY2023

Product revenue (cartridges plus instruments)

24.131.940.545.0—

Collaboration revenue

12.510.06.1——

Service revenue

0.81.21.7——

Total revenue

37.443.148.357.547.4

Product Lines

Product line (EUR Mn)FY2021FY2022

Cartridge revenue, total

—35.9

Oncology cartridge revenue

24.131.3

SARS-CoV-2 product revenue

6.83.5

Instrument revenue (sales and rentals)

8.99.2

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2020FY2021FY2022

Total revenue growth YoY

15.212.119.0

Product revenue growth YoY

32.427.011.1

Collaboration revenue growth YoY

-20.0-39.0—

Product share of total revenue

74.083.978.3

Revenue by Segment

Metric (EUR Mn)H1 2022H1 2023

Total revenue

26.429.5

Product-related revenue

21.323.5

Collaboration revenue

5.16.0

SARS-CoV-2 revenue

1.70.7

EBITDA

-18.2-14.5

Net loss

-28.8-31.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

Metric (EUR Mn)FY2019FY2020FY2021FY2022FY2023

Total revenue

37.443.148.357.547.4

Total operating income (incl. grants and other)

—55.654.958.0—

Gross profit on product sales

——6.615.2—

Gross profit (total, aggregator)

———27.7—

R&D expenses

39.845.848.0——

SG&A expenses

—30.332.4——

EBITDA (company-implied)

——-46.0-36.5—

Net loss

-64.1-62.9-71.5-47.7—

EPS basic (EUR)

-1.14-1.11-1.26-0.79—

Dividends per share (EUR)

00000

Margin Analysis (%)

Metric (%)FY2019FY2020FY2021FY2022

Revenue growth YoY

34.515.212.119.0

Product gross margin

——16.333.8

EBITDA margin (implied)

——-95.2-63.5

Net margin

-171.4-145.9-148.0-83.0

R&D as % of revenue

106.4106.399.4—

Key Financials

Metric (EUR Mn)FY2019FY2020FY2021FY2022FY2023

Cash and cash equivalents

178.7123.753.526.1—

Short-term credit facilities drawn

——6.0——

Bonds equitised in 2023 restructuring

————132.0

Capital Instruments

InstrumentKey termsStatusSource

Convertible bonds due 2024

EUR 150M, 4% coupon, issued 2019

Partially repurchased and exchanged in 2022 (about EUR 14M used to repurchase more than EUR 16M principal in October 2022)

—

New convertible notes (2022)

EUR 41M new money within the EUR 66M recapitalisation; maturity extended (stated as pushing out convertible maturity)

Equitised or enforced in 2023

H1 2022 / FY2022 results

Senior secured term loan

EUR 30M total; about EUR 18M drawn 19 October 2022

Lenders became owners via enforcement

Q3 2022 update

Equity raise (2022–2023)

EUR 25M

Completed January 2023

FY2022 results

Post-restructuring "New Biocartis"

EUR 132M bonds equitised plus EUR 40M new equity; about EUR 44.5M gross debt, about zero net debt

Executed October 2023

360Dx, 26 September 2023

2024 convertible bonds

Remaining principal after 2022 exchange and repurchase not publicly disclosed

2,024

Equitised or enforced 2023

2022 new convertible notes

About EUR 41M new money plus exchanged amounts

—

Equitised or enforced 2023

Senior secured term loan

EUR 30M facility (about EUR 18M drawn October 2022)

—

Rolled into the New Biocartis structure

New Biocartis gross debt (post-October 2023)

About EUR 44.5M

—

Private

“—” = not publicly disclosed.

Cash Flow

Metric (EUR Mn)FY2019FY2020FY2021FY2022FY2023

Operating cash burn (EBITDA plus capex)

——-56.6-38.5—

Net change in cash

—-55.0-70.2-27.4—

Dividends paid

00000

Share buybacks

00000

Financial Analysis

RatioFY2021FY2022

Cash burn as % of revenue

117.267.0

Region Overview

RegionModelDisclosed growth signalsAssessment

Europe

Direct sales in core markets plus distributors

Robust European cartridge growth even during COVID-19 (H1 2020); continued growth in 2022, helped by the GeneFusion Panel

Historic core; largest revenue base; IVDR certification in 2025–2026 strengthens the regulatory moat

United States

Direct sales from September 2019

US instrument revenue more than doubled in 2022; oncology cartridge growth "led by the US" (FY2022 results); 2019 problem that US cartridge consumption lagged placements

Fastest-growing region in 2022; strategic priority under US-based CEO Moody; FDA CDx MSI PMA (2025) is the key US catalyst

Japan

Distributor (Nichirei Biosciences)

Idylla MSI approval in Japan in 2022

Niche, partner-dependent

China

Joint venture (2019)

NMPA instrument compliance testing in January 2020; instrument approval in 2022

Slow; revenue contribution not publicly disclosed

Russia / other RoW

Distributors

Impact of lost Russian distributor sales after the 2022 invasion described as not material

Minor

Share Price

Metric (EUR)FY2015FY2023

Reference share price

11.500.29

Return window

Return windowValueNote

5-year

about -95% or worse

—

Since IPO

about -97.5%

EUR 11.50 to EUR 0.29

Economic value to shareholders

about -100%

No distribution from enforcement; liquidation with negative equity

Capital Markets

ItemStatus

Analyst consensus

None current. KBC Securities (Tom Simonts) covered the stock historically

Dividend history and policy

No dividends ever paid

Buyback authorisations

None executed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Analyst Conclusions

Guidance

Biocartis Group NV: no guidance. The entity is in judicial liquidation. Its residual assets go to creditors under the liquidator's control, and shareholders are expected to receive nothing.

Operating business: management targets profitability on a roughly 12-month horizon from September 2025. That implies break-even around H2 2026, which has not been publicly confirmed as achieved.

Consensus: none.

Bull case (operating franchise)

  1. CDx flywheel: the FDA PMA for Idylla CDx MSI and IVDR CDx certifications for MSI and EGFR give Idylla a regulated, pharma-linked demand engine that the listed company never had.

  2. Operating leverage after deleveraging: gross margin had already reached 40% in H1 2023, and with net debt near zero after equitisation the business no longer carries the EUR 132M bond burden that drove its losses.

  3. Menu expansion into signatures and early detection (Mayo, MCW, City of Hope, Discovery Life Sciences) widens the addressable use of the 2,200-plus installed base.

Bear case

  1. NGS displacement: single-gene and small-panel PCR keeps losing share to comprehensive genomic profiling, capping Idylla's long-run relevance in lung cancer.

  2. Track record of missed targets: 2022 product revenue fell short of guidance by EUR 5–10M, and the end-2024 break-even target slipped.

  3. Financial-sponsor ownership (KBC names Whitebox and Highbridge) may underinvest in R&D and seek an exit. That creates strategic uncertainty and possible relocation of value outside Belgium.

Catalysts and monitorables (next 12 months)

  1. US commercial uptake of Idylla CDx MSI and any reimbursement coding decisions.

  2. Progress on the ESR1 assay and AstraZeneca EGFR CDx toward FDA submission.

  3. Any announcement of break-even, new financing or sale of Biocartis Holdings Inc.

  4. Liquidator's progress and final closure of Biocartis Group NV, including any creditor distributions.

  5. New IVDR certifications across the remaining CE-IVD menu.

  6. Headcount and site decisions in Mechelen.

Analyst verdict

For holders of Biocartis Group NV, the investment case is closed. The October 2023 enforcement moved every share of the operating subsidiaries, and the group's cash, to the bondholders' vehicle. The December 2025 judicial dissolution confirmed negative net equity, and shareholders were told from September 2023 that they would receive nothing. The BCART line, ISIN BE0974281132, should be treated as a zero-value legal shell. Its only remaining relevance is to creditors following the liquidator's work and to tax-loss crystallisation for former holders.

The more interesting analytical question is why a technically elegant franchise failed as a listed equity. The data point to a capital structure mismatch, not a failed product:

  • Revenue compounded at about 15% a year from 2019 to 2022.

  • Oncology ASPs rose.

  • Product gross margins roughly doubled to the mid-30s, and reached 40% in H1 2023.

But R&D ran at about 100% of revenue for years, and a EUR 150M convertible issued in 2019 assumed a growth curve the market never delivered. When the 2022 guidance miss coincided with tighter capital markets, the equity was subordinated to debt it could not refinance.

The private successor is better positioned than its predecessor ever was:

  • It is effectively unlevered.

  • It holds the first FDA-approved fully automated cartridge CDx for colorectal cancer, plus IVDR CDx certifications.

  • It has a widening academic and biopharma partner network.

Its structural challenge remains intact, however. Idylla must defend a speed-and-simplicity niche as oncology testing standardises on NGS, under owners whose horizon is likely an exit rather than decades of platform building. Verdict: listed entity, no value (liquidation). Operating franchise, a credible niche survivor whose next 12–18 months of CDx uptake will decide whether it is sold as a growth asset or as a distressed technology tuck-in.


SOURCE LOG (primary first)

  1. Biocartis Group NV: regulated release, judicial dissolution and liquidator appointment (17 December 2025), Euronext.

  2. Biocartis Group NV: postponement of 2023 annual report and AGM (9 May 2024).

  3. Biocartis Group NV: enforcement by secured creditors (31 October 2023), VFB (Dutch version).

  4. Biocartis Group NV: recapitalisation agreement and H1 2023 results (26 September 2023), VFB; 360Dx summary.

  5. Biocartis Group NV: FY2022 results and 2023 outlook (23 February 2023), Euronext/VFB.

  6. Biocartis Group NV: 2022 key objectives (17 January 2023).

  7. Biocartis Group NV: Q1 2023, Q3 2022, H1 2022 and Q1 2022 updates.

  8. Biocartis Group NV: FY2021 results (24 February 2022) and FY2019 results (5 March 2020), GlobeNewswire.

  9. Biocartis Group NV: CEO appointment, Roger Moody (11 April 2023).

  10. Transparency notification, JJDC (3 October 2023); JPMorgan and Invesco (10 January 2024).

  11. Euronext: Biocartis IPO release (2015).

  12. FSMA: trading suspension notice (17 November 2016).

  13. Biocartis.com newsroom (2025–2026 releases); Roger Moody biography page.

  14. GenomeWeb / 360Dx: annual and half-year results coverage 2019–2023; CEO interview (September 2025).

  15. BioWorld: FDA approval of Idylla CDx MSI; Apis agreement and CEO change; GeneFusion CE mark.

  16. Made in (Mediahuis): KBC Securities commentary (28 August 2025); 2017 CEO appointment article.

  17. Aggregators (lower confidence): Yahoo Finance (BIOGF profile), Parqet, Craft, roic.ai, financialfilings.com, CB Insights, sustainabilityreports.com.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Governance Detail

RoleNameSinceNotes

Court-appointed liquidator

Kristiaan Caluwaerts (legaloffice.be)

15 December 2025

Replaces the board's management powers for liquidation purposes

Board (pre-liquidation, last known)

—2023

Composition at dissolution not publicly disclosed in sources reviewed

Executive Leadership Team

NameTitleTenurePrior rolesEducation

Roger Moody

Chief Executive Officer

Since 24 April 2023

CEO of GlySure Ltd (assets sold to Baxter); CFO of Nanosphere (now DiaSorin), Clinical Genomics and Talis Biomedical; early career at IBM Global Services

BS Finance, Syracuse University; MBA, University of Chicago Booth

Michael Korn, M.D.

Chief Medical and Scientific Officer

In role by March 2025

—

M.D.

Ben Svarczkopf

SVP, Global Marketing

Since June 2025

——

Mike Kreitzinger

SVP, Global Business Development

Since August 2025

——

CFO

Vacant / not publicly disclosed

Prior CFO resigned 2023

——

“—” = not publicly disclosed.

Leadership History

CEOPeriodContext

Rudi Pauwels (founder)

2010–2011 and later executive chairman roles

Founder; stepped back to a strategy-committee chair role

Nayan Gregory Parekh

From November 2011

Finance and corporate-development background (Novartis, New Rhein Healthcare)

Rudi Pauwels (CEO at IPO)

Through 2016

Led the 2015 IPO

Hilde Windels (interim)

Around 2016–2017

Former CFO and deputy CEO

Herman Verrelst

August 2017 – April 2023

Commercial expansion, US direct model, 2022 recapitalisation

Roger Moody

April 2023 – present

Restructuring, creditor takeover, CDx pivot

Major Shareholders

HolderStake / positionDateSource

Johnson & Johnson Innovation – JJDC, Inc.

3,843,804 shares (about 4.1% of about 93.9M)

15 September 2023

Transparency notification, 3 October 2023

JPMorgan Chase & Co.

—

January 2024

Transparency notification, 10 January 2024

Invesco Ltd.

—

January 2024

Transparency notification, 10 January 2024

Competitive Landscape

Key Competitors

CompetitorOverlap with IdyllaRelative positioning

Cepheid (Danaher)

GeneXpert cartridge PCR: the dominant rapid sample-to-answer platform; strong in infectious disease, with some oncology assays

Massive installed base; won the infectious-disease segment Biocartis exited

Qiagen

therascreen PCR CDx kits (EGFR, KRAS, PIK3CA), QIAstat-Dx syndromic, NGS

Incumbent CDx partner of pharma; lab-based workflows

Roche Diagnostics

cobas EGFR / KRAS / BRAF mutation tests; FoundationOne (Foundation Medicine)

Global scale; FDA CDx portfolio; channel power

Thermo Fisher Scientific

Oncomine Dx Target Test, Genexus integrated NGS

NGS-based multi-gene CDx displacing single-gene PCR

Illumina

TruSight Oncology NGS panels

Comprehensive genomic profiling trend

Agilent (Dako)

IHC for MMR/MSI (Dako Omnis); also NGS

Competing modality for MSI (IHC versus PCR)

Foundation Medicine (Roche)

Central-lab comprehensive genomic profiling, tissue and liquid

Send-out alternative to in-house testing

Guardant Health

Liquid-biopsy CGP (Guardant360)

Competes in EGFR and other mutation detection

bioMérieux (BioFire)

Syndromic infectious-disease PCR

Former infectious-disease competitor

Seegene / Hologic / DiaSorin

Infectious-disease and molecular PCR

Former infectious-disease competitors

Exact Sciences

Former partner (Genomic Health); OncoExTra CGP; colorectal screening

Named competitor by CB Insights

Peer Comparison FY2021

CompanyLatest annual revenueGrowthProfitabilityR&D intensity

Biocartis (FY2022, last full audited year)

EUR 57.5M

+19%

Net margin about -83%; product gross margin about 34%

R&D about 99% of revenue (FY2021)

Recent Developments

Earlier restructuring events are therefore included at the end for context.

Company Snapshot

$51.2M

Revenue

526

Employees

2007

Founded

Mechelen, Belgium

Headquarters

SWOT Analysis

Strengths

  • Installed base: 2,218 Idylla instruments globally at the end of H1 2023, after 133 net new placements in H1 2023 (H1 2023 results).
  • Pricing power in oncology: oncology ASP rose to EUR 116 (+11%) in FY2022, and oncology cartridge revenue grew 30% to EUR 31.3M (FY2022 results).
  • Margin trajectory: product gross profit rose from EUR 6.6M (FY2021) to EUR 15.2M (FY2022); gross margin reached 40% in H1 2023 (versus 32% in H1 2022).
  • Regulatory moat: FDA PMA for Idylla CDx MSI (September 2025), plus IVDR Class C CDx for EGFR (June 2025) and MSI (March 2026).
  • Clean post-restructuring balance sheet: EUR 132M of bonds equitised and EUR 40M injected, leaving about EUR 44.5M gross debt and about zero net debt (September 2023 recapitalisation terms).
  • Scientific validation: 166 peer-reviewed Idylla publications by end-2022, plus multiple USCAP 2025 abstracts.
  • Pharma relationships: CDx collaborations with BMS, AstraZeneca and Amgen.

Weaknesses

  • Chronic losses: net losses of EUR 64.1M (FY2019), EUR 62.9M (FY2020), EUR 71.5M (FY2021) and EUR 47.7M (FY2022). KBC Securities estimates cumulative losses near half a billion euros.
  • Revenue scale: FY2022 revenue of EUR 57.5M missed the company's own original EUR 50–55M product-revenue guidance (product revenue reached EUR 45M).
  • Collaboration revenue volatility: collaboration revenue fell 39% in FY2021 (to EUR 6.1M) after a 20% drop in FY2020.
  • Single-site manufacturing risk: the 2021 fire stopped the high-throughput line.
  • Execution critique: KBC Securities (2025) faulted delayed fundraising, insufficient partnerships and weak marketing.
  • US cartridge pull-through: in 2019 US cartridge consumption lagged instrument placements, forcing a change of go-to-market model.

Opportunities

  • US CDx MSI launch: first fully automated cartridge CDx for CRC, combining faster therapy selection with lower cost (CEO, September 2025).
  • ESR1 testing for breast cancer, supported by SERENA-6 data.
  • Gene-signature expansion with Mayo Clinic, MCW and City of Hope (2026).
  • Biopharma services via the Discovery Life Sciences collaboration (July 2026).
  • Cost-down through automation, enabling lower test prices and competitive tenders (CEO commentary).
  • US reimbursement for PCR-based cancer panels (advocacy underway).

Threats

  • NGS displacement by Thermo Fisher (Oncomine/Genexus), Illumina and Foundation Medicine in multi-gene oncology testing.
  • IHC competition for MSI/MMR: Agilent's Dako Omnis was cleared alongside Idylla in the same BMS trial context.
  • Creditor-owner exit horizon: fund owners (Whitebox, Highbridge per KBC) may prioritise a sale over long-term R&D; KBC expects less investment in innovation.
  • Missed break-even: the end-2024 break-even target slipped to roughly late 2026 per the CEO's September 2025 remarks.
  • Hospital capex constraints: deferred investment decisions and heavy use of free evaluations depressed 2022 instrument revenue.
  • Regulatory burden: IVDR recertification of the whole menu is costly for a small company.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
18 Mar 2025USCAP 2025: multiple independent abstracts on Idylla in oncologyClinical evidence base
2 Jun 2025Idylla EGFR Mutation Test receives IVDR Class C CDx certificationFirst IVDR CDx; EU access secured
17 Jun 2025Ben Svarczkopf hired as SVP Global MarketingCommercial rebuild
18 Aug 2025Mike Kreitzinger hired as SVP Global Business DevelopmentPartnering focus
25 Aug 2025Ordinary general meeting; shareholders back dissolution and liquidation; board Q&A on financial statusFormal end of the equity story
28 Aug 2025KBC Securities commentary: holdco holds essentially only debts; Mechelen jobs maintained under US controlMarket interpretation
15 Sep 2025FDA PMA for Idylla CDx MSI Test (with BMS) for colorectal cancerFirst US CDx; first fully automated cartridge-based CDx for CRC in the US
Sep 2025CEO Moody says profitability within about a year; ESR1 test in pipelineStrategic pivot to CDx
14 Nov 2025AMP 2025 showcaseUS lab adoption
15 Dec 2025Court pronounces judicial dissolution for negative net equityLiquidation commences
17 Dec 2025Liquidator Kristiaan Caluwaerts appointment announcedGovernance transferred
12 Jan 2026Mayo Clinic collaboration (breast cancer gene signatures)Menu expansion
3 Mar 2026Patent grant (gene expression / molecular biology)IP
10 Mar 2026IVDR CDx certification for Idylla CDx MSIEU CDx
24 Mar 2026Medical College of Wisconsin collaborationMenu expansion
9 Jun 2026City of Hope pancreatic cancer early-detection agreementNew indication
7 Jul 2026Discovery Life Sciences strategic collaborationBiopharma channel
11 Apr 2023Moody appointed CEO–
15 Jun 2023Cost-reduction programme–
26 Sep 2023H1 results and recapitalisation agreement; trading suspended–
3 Oct 2023J&J/JJDC transparency notice–
31 Oct 2023Creditor enforcement completed–
22 Nov 2023First Biocartis Holdings Inc. release–
10 Jan 2024JPMorgan and Invesco transparency notices–
9 May 2024AGM and annual report postponed for the dissolution process–

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue Stream: Total revenue rose from EUR 37.4 Mn in FY2019 to EUR 47.4 Mn in FY2023.
Biocartis Group NV — Revenue Stream
Series (EUR Mn)FY2019FY2020FY2021FY2022FY2023
Total revenue37.443.148.357.547.4
Product revenue (cartridges plus instruments)24.131.940.545—
Collaboration revenue12.5106.1——
Service revenue0.81.21.7——

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.